Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Dec 11, 2019 5:32 PM EST

News Releases

Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

November 25, 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 25, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

November 8, 2019

Statistically and clinically significant effects on pruritus, xanthomas and growth maintained for up to four years of treatment in Alagille syndrome Durable multi-parameter treatment response and correlation of response with increased bile acid synthesis in progressive familial intrahepatic

Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

November 6, 2019

Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted Cash, Cash Equivalents and Investments Balance of $153.6 million FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer

October 28, 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 28, 2019-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the appointment of Ed Tucker , M.D.

Events

Evercore ISI 2nd Annual HealthCONx Conference

Dec 4, 2019 at 8:00 AM EST

Listen to webcast

2019 Cantor Global HC Conference

Oct 4, 2019 at 10:40 AM EDT

Click here for webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu